Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TS-134 Administered Orally to Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs TS 134 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Taisho Pharmaceutical
- 30 Apr 2020 Results assessing the safety and pharmacokinetics of single and multiple doses of a novel mGlu2/3 receptor agonist prodrug, MGS0274 besylate (TS-134), were investigated in healthy subjects published in the British Journal of Clinical Pharmacology
- 22 Nov 2018 New trial record